Daniel R. Omstead, Ph.D., is Chief Executive Officer of Tekla Capital Management LLC and President and Portfolio Manager of Tekla Healthcare Investors, Tekla Life Science Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund; four NYSE listed closed-end mutual funds that make equity investments in healthcare-related companies.
Prior to joining Tekla, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc.
Before Joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc., a public biotech company that developed CNS therapies.
Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson and at Merck Sharpe and Dohme Research Laboratories, a division of Merck and Company, Inc.
While at Johnson & Johnson, Dr. Omstead participated in the development of Orthoclone OKT3TM, EprexTM/ProcritTM and other biological products. While at Merck, Dr. Omstead worked on the development of RecombivaxTM, MefoxinTM, HeartguardTM and other traditional drug products.
Dr. Omstead holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
Page last updated: September 22, 2018